References
1. Chernikova N.A. The role of self-control in the modern management of diabetes. Diabet i obraz zhizni [Diabetes. Lifestyle]. 2017; (4): 38. (in Russian)
2. Svetlova O.V., Gurieva I.V. A new level of technology - a new level of self-control in the management of diabetes. Medicinskiy sovet [Medical Counsil]. 2015; (7): 48-50. (in Russian)
3. Svetlova O.V., Gurieva I.V. Basic principles of diagnosis and treatment of diabetic autonomic neuropathy. Doktor. Ru [Doctor. Ru]. 2013; 1 (79): 94-100. (in Russian)
4. Pandya K.G., Budhram R., Clark G.J., Lau-Cam C.A. Taurine can enhance the protective actions of metformin against diabetes-induced alterations adversely affecting renal function. Adv Exp Med Biol. 2015; 803: 227-50.
5. Ametov A.S., Prudnikova M.A. Metabolic therapy in the complex treatment of cardiovascular complications of type 2 diabetes. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2017; (2): 37-44. (in Russian)
6. Ametov A.S., Soluyanova T.N. Taurine in the treatment of diabetes. Medicinskiy sovet [Medical Counsil]. 2011; (1-2): 54-8. (in Russian)
7. Jong C.J., Azuma J., Schaffer S. Mechanism underlying the antioxidant activity of taurine: prevention of mitochondrial oxidant production. Amino Acids, 2012; 42: 2223-32.
8. Statsenko M.E., Turkina S.V., Gorbacheva E.E., Ermolenko A.A. Pathogenetic possibilities of taurine in the treatment of diabetic micro-and macrovascular complications. Russkiy Medicinskiy Zhurnal [RussianMedical Journal]. 2018; (5): 10-6. (in Russian)
9. Gurieva I.V., Svetlova O.V., Khlopina M.M. Diabetic pain neuropathy: the effect of "hyperglycemic memory" on pathogenetic approaches to treatment. Russkiy Medicinskiy Zhurnal [Russian Medical Journal]. 2013; (3): 27. (in Russian)
10. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010; 107: 1058-70.
11. Panda S., Mishra S.R., Mishra V.V.V. A review on "Taurine - a magic molecule". Eur J Pharm Med Res. 2018; 5 (02): 534-6.
12. Murakami S., Yamagishi I., Asami. et al. Hypolipidemic effect of taurine in stroke-prone spontaneously hypertensive rats. Pharmacology. 1996; 52: 303-13.
13. Schaffer S.W., Azouma J., Mozaffari M. Role of antioxidant activity of taurine in diabetes // Can J Physiol Pharmacol. 2009; 87: 91-9.
14. Azuma J., Sawamura A., Awata N. Usefullness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J. 1992; 56: 95-9.
15. Sun Q., Wang B., Li Y., Sun F., et al. Taurine supplementation lower blood pressure and improves vascular function in prehypertension. Hypertension Mars. 2016; 67: 541-9.
16. Svetlova O.V., Gurieva I.V., Puzin S.N., Vasilenko O.Yu., et al. The relationship between autonomic neuropathy and asymptomatic hypoglycemia in patients with 1-type diabetes. Sakharniy Diabet [Diabetes Mellitus]. 2008; (4): 76-9. (in Russian)
17. El Agouza I.M., Taha A., Mahfouz A.A., Shalash N.M., et al. The possibility of using serum taurine level as an early marker to control complications of diabetic foot. J. Diabetic Соmplications Med. 2017, 2; 1: 116.
18. Zvenigorodskaya L.A., Mcrtumyan A.M., Shinkin M.V., Nilova T.V., et al. Targets of metabolic tandem: nonalcoholic fatty liver disease and type 2 diabetes. Russkiy medicinskiy zhurnal [Russian Medical Journal]. 2018; (1): 55-9. (In Russian)
19. Ito T., Schaffer W.S. The potential usefulness of taurine on diabetes mellitus and its complication. Amino Acid. 2012; 42: 1529-39.
20. Svetlova O.V., Gurieva I.V., Kuzina I.V. Long-term effect of hyperglycemic memory on pathogenetic approaches to the treatment of diabetic polyneuropathy. Trudnyy patsient [Difficult Patient]. 2012; (1): 14-9. (in Russian)
21. Gurieva I.V., Svetlova O.V. Pathogenetic therapy of intermittent claudication syndrome in patients with diabetes mellitus. Poliklinika [Polyclinic]. 2012; (4-1): 15-8. (in Russian)
22. Gurieva I.V., Svetlova O.V. Promising strategies in the treatment of diabetic polyneuropathy: the role of antioxidant therapy. Pharmateka [Phar-mateca]. 2013; (5): 76-80. (in Russian)
23. Lima L., Cubillos S. Taurine might be acting as atrophic factor in the retina by modulating phosphorylation of cellular proteins. Neurosci Res. 1998; 53. P. 337-84.
24. Arfuzir N.N.N., Agarwal R., et al. Taurine protects against retinal and optic nerve damage induced by endothelin-1 in rats via antioxidant effects. Neur Reg Res. 2019; IP: 83.102.145.250: 2014-21.
25. El Agouza I.M., Saad A.H., Mahfouz A.A., Hamdy K. Serum Taurine Level in relation to ophtalmoscopic examination as early marker for diabetic retinopathy. Clin Med Biochem. 2017; 3 (1): 124. doi: 10.4172/2471-2663.1000124
26. Vorohobina N.V., Kuznetsova A.V. The use of Dibicor in patients with type 2 diabetes mellitus and metabolic syndrome. Russkiy meditsinskiy zhurnal [Russian Medical Journal]. 2010; (18, 28): 1816-9. (in Russian)
27. Ito N., Kimura Y., Uozumi Y., et al. Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol. 2008; 44: 927-37.